{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:28:45Z","timestamp":1785274125107,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":2990,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.exphem.2013.12.007","type":"journal-article","created":{"date-parts":[[2014,1,6]],"date-time":"2014-01-06T14:01:56Z","timestamp":1389016916000},"page":"282-293.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA"],"prefix":"10.1016","volume":"42","author":[{"given":"Irina","family":"Sadovnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Lierman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Suppan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Stefanzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Pickl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Cools","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2013.12.007_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000085559","article-title":"Molecular classification and pathogenesis of eosinophilic disorders: 2005 update","volume":"114","author":"Gotlib","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.exphem.2013.12.007_bib2","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2006.06038.x","article-title":"Eosinophilia: secondary, clonal and idiopathic","volume":"133","author":"Tefferi","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2013.12.007_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.iac.2007.06.001","article-title":"Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome","volume":"27","author":"Bain","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.exphem.2013.12.007_bib4","first-page":"69","article-title":"Chronic eosinophilic leukemia\/hypereosinophilic syndrome","volume":"142","author":"Gotlib","year":"2008","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.exphem.2013.12.007_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.blre.2009.01.001","article-title":"Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders","volume":"23","author":"Valent","year":"2009","journal-title":"Blood Rev"},{"key":"10.1016\/j.exphem.2013.12.007_bib6","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2013.12.007_bib7","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2003-06-1824","article-title":"The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management","volume":"103","author":"Gotlib","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.12.007_bib8","series-title":"The World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues","first-page":"29","article-title":"Chronic eosinophilic leukaemia and the idiopathic hypereosinophilic syndrome","author":"Bain","year":"2001"},{"key":"10.1016\/j.exphem.2013.12.007_bib9","series-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues","first-page":"51","article-title":"Chronic eosinophilic leukaemia, not otherwise specified","author":"Bain","year":"2008"},{"key":"10.1016\/j.exphem.2013.12.007_bib10","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1073\/pnas.0932698100","article-title":"Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome","volume":"100","author":"Griffin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2013.12.007_bib11","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1182\/blood-2003-07-2479","article-title":"The EOL-1 cell line as an in\u00a0vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"103","author":"Cools","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.12.007_bib12","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.leukres.2006.03.012","article-title":"Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells","volume":"30","author":"Verstovsek","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2013.12.007_bib13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.leukres.2007.07.013","article-title":"All-trans-retinoic acid enhances apoptosis induction by tyrosine kinase inhibitors in the eosinophilic leukemia-derived EoL-1 cell line","volume":"32","author":"Robert","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2013.12.007_bib14","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.exphem.2008.04.017","article-title":"Dasatinib inhibits the\u00a0growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha","volume":"36","author":"Baumgartner","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2013.12.007_bib15","doi-asserted-by":"crossref","first-page":"e30567","DOI":"10.1371\/journal.pone.0030567","article-title":"Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model","volume":"7","author":"Wicklein","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2013.12.007_bib16","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2002-10-3103","article-title":"Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders","volume":"101","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.12.007_bib17","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.12.007_bib18","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2013.12.007_bib19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","article-title":"Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study","volume":"143","author":"Metzgeroth","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2013.12.007_bib20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00062752-200401000-00008","article-title":"The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia","volume":"11","author":"Cools","year":"2004","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.exphem.2013.12.007_bib21","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/leu.2009.2","article-title":"FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib","volume":"23","author":"Lierman","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.12.007_bib22","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1398-9995.2009.01943.x","article-title":"A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia\/hypereosinophilic syndrome","volume":"64","author":"Salemi","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.exphem.2013.12.007_bib23","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/onc.2010.476","article-title":"The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in\u00a0vitro","volume":"30","author":"von Bubnoff","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2013.12.007_bib24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(03)00108-9","article-title":"PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR\u03b1-induced myeloproliferative disease","volume":"3","author":"Cools","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2013.12.007_bib25","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","article-title":"Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant","volume":"108","author":"Lierman","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.12.007_bib26","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1182\/blood-2006-01-0285","article-title":"The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)","volume":"107","author":"von Bubnoff","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.12.007_bib27","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/leu.2012.8","article-title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases","volume":"26","author":"Lierman","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.12.007_bib28","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.V66.6.1233.1233","article-title":"Establishment and characterization of a new human eosinophilic leukemia cell line","volume":"66","author":"Saito","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.12.007_bib29","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1093\/emboj\/17.18.5321","article-title":"Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL\/JAK2 fusion genes","volume":"17","author":"Schwaller","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2013.12.007_bib30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1439-0264.2002.00398.x","article-title":"Morphological and biochemical aspects of apoptosis, oncosis and necrosis","volume":"31","author":"Van Cruchten","year":"2002","journal-title":"Anat Histol Embryol"},{"key":"10.1016\/j.exphem.2013.12.007_bib31","doi-asserted-by":"crossref","first-page":"e29925","DOI":"10.1371\/journal.pone.0029925","article-title":"The PI3-kinase\/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils","volume":"7","author":"Blatt","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2013.12.007_bib32","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1398-9995.2012.02833.x","article-title":"NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation","volume":"67","author":"Hadzijusufovic","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.exphem.2013.12.007_bib33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/eji.1830190420","article-title":"Recombinant human interleukin 5 is a selective eosinophil chemoattractant","volume":"19","author":"Wang","year":"1989","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.exphem.2013.12.007_bib34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/BF03401631","article-title":"Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice","volume":"2","author":"Rothenberg","year":"1996","journal-title":"Mol Med"},{"key":"10.1016\/j.exphem.2013.12.007_bib35","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/all.12139","article-title":"Oncostatin M is a FIP1L1\/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia","volume":"68","author":"Hoermann","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.exphem.2013.12.007_bib36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/ehm.11.81","article-title":"Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field","volume":"5","author":"Valent","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.exphem.2013.12.007_bib37","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X14000034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X14000034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:31:22Z","timestamp":1759566682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X14000034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0301472X14000034"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2013.12.007","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2013.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}